Sugi Predict

Sugi Predict / Compounds / SCHEMBL1856342

SCHEMBL1856342

SCHEMBL1856342

C[C@H](O)c1ccc(F)cn1

nearest known ligand 0.57

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ APLNR P35414 2/20 0.57
▸ ESR1 P03372 2/20 0.38
▸ ESR2 Q92731 2/20 0.38
▸ HDAC6 Q9UBN7 1/20 0.38
▸ JAK2 O60674 4/20 0.36
▸ JAK3 P52333 3/20 0.36
▸ HRH1 P35367 1/20 0.36
▸ KCNH2 Q12809 1/20 0.36
▸ FFAR2 O15552 1/20 0.35
▸ TRPA1 O75762 1/20 0.34
▸ NR1I2 O75469 2/20 0.33
▸ TRPV3 Q8NET8 1/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ P2RX3 P56373 1/20 0.32
▸ P2RX2 Q9UBL9 1/20 0.32
▸ KMO O15229 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29858360 1.00 APLNR (0.57) APLNRESR1ESR2HDAC6JAK2
SCHEMBL589519 1.00 APLNR (0.57) APLNRESR1ESR2HDAC6JAK2
SCHEMBL25203689 1.00 APLNR (0.57) APLNRESR1ESR2HDAC6JAK2
SCHEMBL3234164 0.85 APLNR (0.52) APLNRKCNH2FFAR2NR1I2MAPK1
SCHEMBL14815592 0.84 APLNR (0.44) APLNR
SCHEMBL179299 0.82 APLNR (0.51) APLNRESR1ESR2HDAC6JAK2
SCHEMBL3234173 0.81 APLNR (0.49) APLNRESR1ESR2HDAC6HRH1
SCHEMBL22506484 0.80 APLNR (0.64) APLNRHDAC6JAK2JAK3KMT2A
SCHEMBL20470117 0.80 APLNR (0.64) APLNRHDAC6JAK2JAK3KMT2A
SCHEMBL20470327 0.80 APLNR (0.64) APLNRHDAC6JAK2JAK3KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4301468-B1 FGFR3 INHIBITOR COMPOUNDS LILLY CO ELI (US) 2025-09-03 — — EP disclosed
US-20250270211-A1 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. 2025-08-28 — — US disclosed
US-12351581-B2 Compounds for FGFR inhibition COGENT BIOSCIENCES, INC. (US) 2025-07-08 — — US disclosed
WO-2025034912-A9 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. (US) 2025-04-24 — — WO disclosed
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS ELI LILLY AND COMPANY 2025-04-17 — — US disclosed
US-20250066352-A1 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. 2025-02-27 — — US disclosed
WO-2025034912-A2 COMPOUNDS FOR FGFR INHIBITION COGENT BIOSCIENCES, INC. (US) 2025-02-13 — — WO disclosed
US-12209086-B2 FGFR3 inhibitor compounds ELI LILLY AND COMPANY (US) 2025-01-28 — — US disclosed
US-20240190870-A1 FGFR3 INHIBITOR COMPOUNDS LOXO ONCOLOGY, INC. 2024-06-13 — — US disclosed
CN-118164989-A Imidazo [1,2-b ] pyridazine derivatives as TRK inhibitors and application thereof 上海医药工业研究院有限公司 2024-06-11 — — CN disclosed
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2010-02-11 — — US disclosed
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2010-02-11 — — US disclosed
US-20090105208-A1 Substituted Piperazines as CB1 Antagonists SCHERING CORPORATION 2009-04-23 — — US disclosed
US-20090105208-A1 Substituted Piperazines as CB1 Antagonists SCHERING CORPORATION 2009-04-23 — — US disclosed
WO-2009005646-A2 SUBSTITUTED PIPERAZINES AS CB1 ANTAGONISTS SCHERING CORPORATION (US) 2009-01-08 — — WO disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
US-20080318981-A1 Novel Compounds 480 ASTRAZENECA AB (SE) 2008-12-25 — — US disclosed
WO-2008039139-A1 NOVEL 5,7-DISUBSTITUTED [1, 3] THIAZOLO [4, 5] PYRIMIDIN-2 (3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2008-04-03 — — WO disclosed
WO-2008039138-A1 NOVEL 5, 7-DISUBSTITUTED [1, 3 ] THIAZOLO [4, 5-D] PYRIMIDIN-2 (3H)-ONE DERIVATIVES AND THEIR USE IN THERAPY ASTRAZENECA AB (SE) 2008-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250066352-A1 COMPOUNDS FOR FGFR INHIBITION FGFR1, FGFR4, FGFR3 APLNR 1247/4885ESR1 379/4885ESR2 281/4885
US-20080318981-A1 Novel Compounds 480 CX3CR1, CCR2, CXCR3 APLNR 352/4885ESR1 2055/4885ESR2 919/4885
US-20250270211-A1 COMPOUNDS FOR FGFR INHIBITION FGFR1, FGFR4, FGFR3 APLNR 1247/4885ESR1 379/4885ESR2 281/4885
US-12209086-B2 FGFR3 inhibitor compounds FGFR3, FGFR1, FGFR2 APLNR 289/4885ESR1 4173/4885ESR2 4436/4885
US-20100035899-A1 5,7-DISUBSTITUTED[1.3]THIAZOLO[4,5-d]PYRIMIDIN-2(3H)-AMINE DERIVATIVES AND THEIR USE IN THERAPY CX3CR1, CCR2, CXCR3 APLNR 357/4885ESR1 1519/4885ESR2 851/4885
US-20090105208-A1 Substituted Piperazines as CB1 Antagonists CNR1, CNR2, GPR119 APLNR 404/4885ESR1 1173/4885ESR2 1150/4885
US-20240190870-A1 FGFR3 INHIBITOR COMPOUNDS FGFR3, FGFR1, FGFR2 APLNR 289/4885ESR1 4173/4885ESR2 4436/4885
US-12351581-B2 Compounds for FGFR inhibition FGFR1, FGFR4, FGFR3 APLNR 1247/4885ESR1 379/4885ESR2 281/4885
US-20250122196-A1 FGFR3 INHIBITOR COMPOUNDS FGFR3, FGFR1, FGFR2 APLNR 289/4885ESR1 4173/4885ESR2 4436/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.